Dtxcid6026793

Base Information

• Chemical Name: Dtxcid6026793
• CAS No.: 38916-34-6
• Molecular Formula: C76H104N18O19S2
• Molecular Weight: 1637.9
• European Community (EC) Number: 254-186-5,256-969-7
• ChEMBL ID: CHEMBL3185829
• DSSTox Substance ID: DTXSID8046793
• Metabolomics Workbench ID: 152152
• Pharos Ligand ID: L2NYLN78KPXZ
• Mol file: 38916-34-6.mol

Synonyms:Cyclic Somatostatin;Somatofalk;Somatostatin;Somatostatin 14;Somatostatin, Cyclic;Somatostatin-14;Somatotropin Release Inhibiting Factor;Somatotropin Release Inhibiting Hormone;Somatotropin Release-Inhibiting Factor;Somatotropin Release-Inhibiting Hormone;SRIH-14;Stilamin

Chemical Property of Dtxcid6026793

Chemical Property:

• Appearance/Colour: White powder
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.669
• Boiling Point: 1970.9 °C at 760 mmHg
• PKA: 2.94±0.70(Predicted)
• Flash Point: 1145.7 °C
• PSA: 663.83000
• Density: 1.43 g/cm³
• LogP: 2.28620
• Storage Temp.: −20°C
• Solubility.: H2O: 1 mg/mL
• Water Solubility.: Soluble in water(25,00°C 1,00 g/L), Methanol.
• XLogP3: -3.1
• Hydrogen Bond Donor Count: 22
• Hydrogen Bond Acceptor Count: 24
• Rotatable Bond Count: 26
• Exact Mass: 1636.71665551
• Heavy Atom Count: 115
• Complexity: 3240

Purity/Quality:

98%, ^*data from raw suppliers

Somatostatin ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)CC5=CC=CC=C5)CC(=O)N)CCCCN)NC(=O)CNC(=O)C(C)N)C(=O)O)CO)C(C)O)CC6=CC=CC=C6)O
• Isomeric SMILES: C[C@@H](C(=O)NCC(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCCCN)CC(=O)N)CC2=CC=CC=C2)CC3=CC=CC=C3)CC4=CNC5=CC=CC=C54)CCCCN)C(C)O)CC6=CC=CC=C6)C(C)O)CO)C(=O)O)N
• Recent ClinicalTrials: Liver Glycogen and Hypoglycemia in Humans
• Recent EU Clinical Trials: Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomized controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Retinopathy.
• Recent NIPH Clinical Trials: Clinical effect of everolimus and somatostatin analogues as a first line therapy for patients with pNET (phase II study)
• Uses: Growth hormone-release inhibiting factor; treatment of severe, acute hemorrhage of gastroduodenal ulcers; experimental antidiabetic Growth hormone-release inhibiting factor; treatment of severe, acute hemorrhage of gastroduodenal ulcers; experimental antidiabetic.
• Biological Functions: Somatostatin is a cyclic 14-peptide that was first isolated by Guillemin in 1973 and is probably the most thoroughly investigated and most important of the inhibitory factors produced by the hypothalamus. The principal activity of somatostatin, which is of hypothalamic origin, is inhibition of the release of growth hormone (GH) from the anterior pituitary. Too much GH, as in pituitary tumors, causes acromegaly, a form of giantism. On the other hand, too little GH leads to dwarfism. Somatostatin also has been found in the pancreas and the GI tract, where it inhibits the secretion of both insulin and glucagon from the pancreas as well as the secretion of a variety of intestinal peptides (e.g., gastrin, secretin, pepsin, and renin). The short half-life of somatostatin, which is less than 3 minutes, has precluded its use as a therapeutic agent. Many derivatives of somatostatin have been prepared to increase its duration of action and/or to enhance its selectivity of action. The culmination of these structure–activity studies was the development of octreotide acetate.

Technology Process of Dtxcid6026793

There total 5 articles about Dtxcid6026793 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 95.0%

C178H268N18O29S2 (1324007-69-3) → somatostatin (38916-34-6,66610-27-3,61950-59-2)

Guidance literature:

With chlorotriisopropylsilane; trifluoroacetic acid; In water;

DOI:10.1021/ol302863r

Reference yield: 68.0%

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys (40958-31-4) → somatostatin (38916-34-6,66610-27-3,61950-59-2)

Guidance literature:

With iodine; acetic acid; In methanol; water; at 20 ℃; for 2h;

DOI:10.1039/c9ob01114e

Reference yield:

BOC-glycine (4530-20-5) + L-N-Boc-Ala (15761-38-3) + C16H22NO4PolS + N-tert-butoxycarbonyl-L-phenylalanine (13734-34-4) + N-Boc-O-benzyl-L-threonine (15260-10-3) + BOC-O-benzyl-L-serine (23680-31-1) + N-(tert-butyloxycarbonyl)-S-(4-methoxybenzyl)cysteine (18942-46-6,58290-35-0) + Boc-(S)-Lys(2-Cl-Z)-OH (54613-99-9) + Boc-Trp-OH (13139-14-5) + (S)-2-tert-Butoxycarbonylamino-N-(9H-xanthen-9-yl)-succinamic acid (65420-40-8) → somatostatin (38916-34-6,66610-27-3,61950-59-2)

Guidance literature:

C₁₆H₂₂NO₄PolS; With 3-methyl-phenol; trifluoroacetic acid; for 0.25h; Automated synthesizer; solid phase reaction;

BOC-O-benzyl-L-serine; With 1-methyl-pyrrolidin-2-one; benzotriazol-1-ol; diisopropyl-carbodiimide; for 1h; Automated synthesizer; solid phase reaction;

BOC-glycine; L-N-Boc-Ala; N-tert-butoxycarbonyl-L-phenylalanine; N-Boc-O-benzyl-L-threonine; N-(tert-butyloxycarbonyl)-S-(4-methoxybenzyl)cysteine; Boc-(S)-Lys(2-Cl-Z)-OH; Boc-Trp-OH; (S)-2-tert-Butoxycarbonylamino-N-(9H-xanthen-9-yl)-succinamic acid; Further stages;

DOI:10.1021/jm200307v

upstream raw materials:

Oxidized glutathione

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys

BOC-glycine

L-N-Boc-Ala

Downstream raw materials:

Oxidized glutathione

Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys

C₈₀H₁₀₅N₁₉O₂₁S₂

Refernces

• 1、 Ma, Dongying,Song, Changying,Sun, Jingjing,Shen, Shigang,Huo, Shuying. "Formation of peptide disulfide bonds through a trans-dibromido-Pt(IV) complex oxidation reaction: Kinetic and mechanistic analyses". . . Retrieved 2021/01/18.
• 2、 Huo, Shuying,Shen, Shigang,Song, Changying,Sun, Jingjing,Zhao, Xiaowei. "A study to develop platinum(iv) complex chemistry for peptide disulfide bond formation". supporting information. p. 1736 - 1741. Retrieved 2020/02/20.